Research programme: matrix metalloproteinase-13 inhibitors - PfizerAlternative Names: PD 200347
Latest Information Update: 14 Aug 2009
At a glance
- Originator Pfizer
- Mechanism of Action Matrix metalloproteinase 13 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Osteoarthritis
Most Recent Events
- 16 Sep 2008 Preclinical development is ongoing
- 24 Jun 2004 Preclinical trials in Osteoarthritis in USA (unspecified route)